Ebola virus disease sequelae and viral persistence in animal models: Implications for the future.

Olivia Durant, Andrea Marzi
Author Information
  1. Olivia Durant: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
  2. Andrea Marzi: Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America. ORCID

Abstract

Ebola virus disease (EVD), caused by infection with Ebola virus, results in severe, acute illness with a high mortality rate. As the incidence of outbreaks of EVD increases and with the development and approval of medical countermeasures (MCMs) against the acute disease, late phases of EVD, including sequelae, recrudescence, and viral persistence, are occuring more frequently and are now a focus of ongoing research. Existing animal disease models recapitulate acute EVD but are not suitable to investigate the mechanisms of these late disease phenomena. Although there are challenges in establishing such a late disease model, the filovirus research community has begun to call for the development of an EBOV persistence model to address late disease concerns. Ultimately, this will aid the development of MCMs against late disease and benefit survivors of future EVD and filovirus outbreaks.

References

  1. Klin Wochenschr. 1968 Apr 1;46(7):398-400 [PMID: 4971902]
  2. Front Microbiol. 2013 Sep 05;4:267 [PMID: 24046765]
  3. J Infect Dis. 2023 Nov 13;228(Suppl 7):S617-S625 [PMID: 37477943]
  4. AIDS Res Ther. 2023 Oct 27;20(1):74 [PMID: 37884997]
  5. N Engl J Med. 2021 Apr 1;384(13):1240-1247 [PMID: 33789012]
  6. Nat Microbiol. 2017 Jul 17;2:17113 [PMID: 28715405]
  7. N Engl J Med. 2019 Mar 7;380(10):924-934 [PMID: 30855742]
  8. Cell Host Microbe. 2018 Sep 12;24(3):405-416.e3 [PMID: 30173956]
  9. J Virol. 2021 Nov 23;95(24):e0083321 [PMID: 34586862]
  10. Lancet Infect Dis. 2016 Jun;16(6):e82-e91 [PMID: 27020309]
  11. Sci Transl Med. 2022 Feb 9;14(631):eabi5229 [PMID: 35138912]
  12. Antivir Ther. 2023 Oct;28(5):13596535231201162 [PMID: 37749751]
  13. Mucosal Immunol. 2008 Sep;1(5):372-81 [PMID: 19079201]
  14. JCI Insight. 2022 May 23;7(10): [PMID: 35413016]
  15. EBioMedicine. 2018 Apr;30:217-224 [PMID: 29622497]
  16. Open Forum Infect Dis. 2023 Mar 22;10(4):ofad146 [PMID: 37065991]
  17. J Infect Dis. 2018 Nov 22;218(suppl_5):S423-S433 [PMID: 30053050]
  18. J Infect Dis. 2007 Nov 15;196 Suppl 2:S323-8 [PMID: 17940967]
  19. Clin Infect Dis. 2021 Dec 16;73(12):2166-2174 [PMID: 33621316]
  20. J Hosp Infect. 2016 Oct;94(2):113-5 [PMID: 27499080]
  21. Sci Transl Med. 2013 Oct 16;5(207):207ra143 [PMID: 24132638]
  22. Postgrad Med J. 1973 Aug;49(574):542-6 [PMID: 4207635]
  23. mBio. 2021 Jan 12;12(1): [PMID: 33436428]
  24. J Infect Dis. 2016 Jan 1;213(1):57-60 [PMID: 26153408]
  25. Crit Care. 2016 Jul 29;20(1):217 [PMID: 27468829]
  26. J Infect Dis. 2023 Nov 15;228(Suppl 7):S554-S558 [PMID: 37102262]

MeSH Term

Animals
Hemorrhagic Fever, Ebola
Ebolavirus
Disease Outbreaks
Disease Progression
Disease Models, Animal

Word Cloud

Created with Highcharts 10.0.0diseaseEVDlateEbolavirusacutedevelopmentpersistenceoutbreaksMCMssequelaeviralresearchanimalmodelfilovirusfuturecausedinfectionresultssevereillnesshighmortalityrateincidenceincreasesapprovalmedicalcountermeasuresphasesincludingrecrudescenceoccuringfrequentlynowfocusongoingExistingmodelsrecapitulatesuitableinvestigatemechanismsphenomenaAlthoughchallengesestablishingcommunitybeguncallEBOVaddressconcernsUltimatelywillaidbenefitsurvivorsmodels:Implications

Similar Articles

Cited By (1)